

DAFTAR PUSTAKA

- Bosso, M., Thanaraj, T. A., Abu-Farha, M., Alanbaei, M., Abubaker, J., & Al-Mulla, F. (2020). The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. *Molecular Therapy - Methods and Clinical Development*, 18(September), 321–327. <https://doi.org/10.1016/j.omtm.2020.06.017>
- Chouchana, L., Beeker, N., Garcelon, N., Rance, B., Paris, N., Salamanca, E., Polard, E., Burgun, A., Treluyer, J. M., & Neuraz, A. (2021). Correction to: Association of Antihypertensive Agents with the Risk of In-Hospital Death in Patients with Covid-19 (Cardiovascular Drugs and Therapy, (2021), 10.1007/s10557-021-07155-5). *Cardiovascular Drugs and Therapy*, 6–11. <https://doi.org/10.1007/s10557-021-07164-4>
- Dambha-Miller, H., Albasri, A., Hodgson, S., Wilcox, C. R., Khan, S., Islam, N., Little, P., & Griffin, S. J. (2020). Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: A systematic review. *BMJ Open*, 10(9), 1–10. <https://doi.org/10.1136/bmjopen-2020-040644>
- Danielle X. Morales, Sara E. Grineski, and T. W. C. (2016). HHS Public Access. *Physiology & Behavior*, 176(1), 139–148. <https://doi.org/10.1161/CIRCRESAHA.116.307708>.Role
- Danser, A. H. J., Epstein, M., & Batlle, D. (2020). Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. *Hypertension*, 75(6), 1382–1385. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15082>
- Fan, C., Lu, W., Li, K., Ding, Y., & Wang, J. (2021). ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Infection in COVID-19 Patients. *Frontiers in Medicine*, 7(January), 1–9.

<https://doi.org/10.3389/fmed.2020.563893>

- Flack, J. M., & Adekola, B. (2020). Blood pressure and the new ACC/AHA hypertension guidelines. *Trends in Cardiovascular Medicine*, 30(3), 160–164. <https://doi.org/10.1016/j.tcm.2019.05.003>
- Gao, Q., Xu, L., & Cai, J. (2021). New drug targets for hypertension: A literature review. *Biochimica et Biophysica Acta - Molecular Basis of Disease*, 1867(3). <https://doi.org/10.1016/j.bbadis.2020.166037>
- Garc, A., Vera-vera, S., Jurado-rom, A., & Jim, S. (2022). *Calcium Signaling Pathway Is Involved in the Shedding of ACE2 Catalytic Ectodomain : New Insights for Clinical and Therapeutic Applications of ACE2 for COVID-19*. 2(March 2020), 1–17.
- Jarari, N., Rao, N., Peela, J. R., Ellafi, K. A., Shakila, S., Said, A. R., Nelapalli, N. K., Min, Y., Tun, K. D., Jamallulail, S. I., Rawal, A. K., Ramanujam, R., Yedla, R. N., Kandregula, D. K., Argi, A., & Peela, L. T. (2015). A review on prescribing patterns of antihypertensive drugs. *Clinical Hypertension*, 22(1), 1–8. <https://doi.org/10.1186/s40885-016-0042-0>
- Jayaseelan, V. P., & Paramasivam, A. (2020). Repurposing calcium channel blockers as antiviral drugs. *Journal of Cell Communication and Signaling*, 14(4), 467–468. <https://doi.org/10.1007/s12079-020-00579-y>
- Kawai, T., Elliott, K. J., Scalia, R., & Eguchi, S. (2021). Contribution of ADAM17 and related ADAMs in cardiovascular diseases. *Cellular and Molecular Life Sciences*, 78(9), 4161–4187. <https://doi.org/10.1007/s00018-021-03779-w>
- Kemenkes RI. (2019). Hipertensi Si Pembunuh Senyap. *Kementrian Kesehatan RI*, 1–5. <https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/info-datin-hipertensi-si-pembunuh-senyap.pdf>

- Khan, S. H., & Zaidi, S. K. (2020). Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19. *Drugs and Therapy Perspectives*, 36(8), 347–350. <https://doi.org/10.1007/s40267-020-00750-w>
- Kocayigit, I., Kocayigit, H., Yaylaci, S., Can, Y., Erdem, A. F., & Karabay, O. (2020). Impact of antihypertensive agents on clinical course and in-hospital mortality: Analysis of 169 hypertensive patients hospitalized for COVID-19. *Revista Da Associacao Medica Brasileira*, 66(Suppl 2), 71–76. <https://doi.org/10.1590/1806-9282.66.S2.71>
- Kriszta, G., Kriszta, Z., Vánca, S., Hegyi, P. J., Frim, L., Eröss, B., Hegyi, P., Pethő, G., & Pintér, E. (2021). Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies. *Frontiers in Pharmacology*, 12(March), 1–11. <https://doi.org/10.3389/fphar.2021.619524>
- Lam, K. W., Chow, K. W., Vo, J., Hou, W., Li, H., Richman, P. S., Mallipattu, S. K., Skopicki, H. A., Singer, A. J., & Duong, T. Q. (2020). Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. *Journal of Infectious Diseases*, 222(8), 1256–1264. <https://doi.org/10.1093/infdis/jiaa447>
- Laurent, S. (2017). Antihypertensive drugs. *Pharmacological Research*, 124, 116–125. <https://doi.org/10.1016/j.phrs.2017.07.026>
- Li, B., He, X., Lei, S. S., Zhou, F. C., Zhang, N. Y., Chen, Y. H., Wang, Y. Z., Su, J., Yu, J. J., Li, L. Z., Zheng, X., Luo, R., Kołodyńska, D., Xiong, S., Lv, G. Y., & Chen, S. H. (2020). Hypertensive rats treated chronically with Nω-Nitro-L-Arginine Methyl Ester (L-NAME) induced disorder of hepatic fatty acid metabolism and intestinal pathophysiology. *Frontiers in Pharmacology*, 10(January), 1–17.

<https://doi.org/10.3389/fphar.2019.01677>

- Muhadi. (2016). JNC 8 : Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa. *Cermin Dunia Kedokteran*, 43(1), 54–59.
- Nair, A., & Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. *Journal of Basic and Clinical Pharmacy*, 7(2), 27. <https://doi.org/10.4103/0976-0105.177703>
- Rodrigues, R., & de Oliveira, S. C. (2021). The impact of angiotensin-converting enzyme 2 (ACE2) expression levels in patients with comorbidities on COVID-19 severity: A comprehensive review. *Microorganisms*, 9(8). <https://doi.org/10.3390/microorganisms9081692>
- Rysz, J., Franczyk, B., Rysz-Górzyńska, M., & Gluba-Brzózka, A. (2020). Pharmacogenomics of hypertension treatment. *International Journal of Molecular Sciences*, 21(13), 1–26. <https://doi.org/10.3390/ijms21134709>
- Salah, H. M., Arthur, J. M., & Mehta, J. L. (2020). Implications of renal ACE2 expression in the age of COVID-19. *European Heart Journal*, 41(48), 4589–4591. <https://doi.org/10.1093/eurheartj/ehaa872>
- Shibata, S., Arima, H., Asayama, K., Hoshida, S., Ichihara, A., Ishimitsu, T., Kario, K., Kishi, T., Mogi, M., Nishiyama, A., Ohishi, M., Ohkubo, T., Tamura, K., Tanaka, M., Yamamoto, E., Yamamoto, K., & Itoh, H. (2020). Hypertension and related diseases in the era of COVID-19: a report from the Japanese Society of Hypertension Task Force on COVID-19. *Hypertension Research*, 43(10), 1028–1046. <https://doi.org/10.1038/s41440-020-0515-0>
- Sinha, S., Cheng, K., Schäffer, A. A., Aldape, K., Schiff, E., & Ruppin, E. (2020). In vitro and in vivo identification of clinically approved drugs that modify ACE 2 expression . *Molecular Systems Biology*, 16(7), 1–9. <https://doi.org/10.15252/msb.20209628>
- Taal, M. W., & Brenner, B. M. (2000). Renoprotective benefits of RAS

inhibition: From ACEI to angiotensin II antagonists. *Kidney International*, 57(5), 1803–1817. <https://doi.org/10.1046/j.1523-1755.2000.00031.x>

Tikellis, C., & Thomas, M. C. (2012). Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. *International Journal of Peptides*, 2012. <https://doi.org/10.1155/2012/256294>

Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D., Ramirez, A., Schlaich, M., Stergiou, G. S., Tomaszewski, M., Wainford, R. D., Williams, B., & Schutte, A. E. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension*, 75(6), 1334–1357. <https://doi.org/10.1161/HYPERTENSIONAHA.120.15026>

Wysocki, J., Lores, E., Ye, M., Soler, M. J., & Batlle, D. (2020). Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. *Journal of the American Society of Nephrology*, 31(9), 1941–1943. <https://doi.org/10.1681/ASN.2020050667>

Yende, S., & Parikh, C. R. (2021). Long COVID and kidney disease. *Nature Reviews Nephrology*, 17(12), 792–793. <https://doi.org/10.1038/s41581-021-00487-3>

Yılmaz, İ. (2019). Angiotensin-converting enzyme inhibitors induce cough. *Turkish Thoracic Journal*, 20(1), 36–42. <https://doi.org/10.5152/TurkThoracJ.2018.18014>

LAMPIRAN

Lampiran 1. Surat Persetujuan Komisi Etik



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL. PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.



Contact Person: dr. Agussalim Bukhari, MMed,PhD, SpGK TELP. 081241850858, 0411 5780103. Fax : 0411-581431

REKOMENDASI PERSETUJUAN ETIK

Nomor : 199/UN4.6.4.5.31/ PP36/ 2022

Tanggal: 28 April 2022

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH22040152	No Sponsor	
Peneliti Utama	dr. Amirah Febrianti Ismail	Sponsor	
Judul Peneliti	PERBEDAAN EKSPRESI ANGIOTENSIN CONVERTING ENZYME-2 (ACE2) PADA JARINGAN GINJAL TIKUS HIPERTENSI SETELAH PEMBERIAN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, CALCIUM CHANNEL BLOCKER, DAN SWITCHING ANGIOTENSIN CONVERTING ENZYME INHIBITOR MENJADI CALCIUM CHANN		
No Versi Protokol	1	Tanggal Versi	27 April 2022
No Versi PSP		Tanggal Versi	
Tempat Penelitian	Laboratorium Biofarmasi Fakultas Farmasi Universitas Hasanuddin, Laboratorium HUMRC RSUH Gedung A Universitas Hasanuddin, Laboratorium Farmasi Universitas Muslim Indonesia Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 28 April 2022 sampai 28 April 2023	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	Tanda tangan 	
Sekretaris KEP Universitas Hasanuddin	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan 	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Laporan SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2. Surat Izin Penelitian di Lab Biofarmasi UNHAS

KEMENTERIAN RISET, TEKNOLOGI, DAN PENDIDIKAN TINGGI FAKULTAS FARMASI UNIVERSITAS HASANUDDIN	
LEMBAR DIS POSISI	
RAHASIA <input type="checkbox"/>	PENTING <input type="checkbox"/>
SEGERA <input type="checkbox"/>	BIASA <input type="checkbox"/>
No.Agenda : 91	Tanggal : 9/9/2022
Tanggal/Nomor : 9/6/2022/4804/UN4.20.1/PT.01.04/2022	
Perihal : Permohonan Izin Penelitian di Lab. Biofarmasi a/n Amirah Febrianti Ismail	
Asal Surat : WDI Pascasarjana	
INSTRUKSI/ INFORMASI w/ difasilitasi sesuai prosedur m	Diteruskan Kepada : 1. Ka Lab Biofarmaka 2. 3. 4. 5.
Paraf KTU : Tanggal : Catatan :	



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN,
RISET DAN TEKNOLOGI
UNIVERSITAS HASANUDDIN
SEKOLAH PASCASARJANA

Jalan Perintis Kemerdekaan Km. 10 Makassar 90245 Telp. : (0411) 585034, 585036
Fax. : (0411) 585868, E-mail : info@pasca.unhas.ac.id, http://pasca.unhas.ac.id

Nomor : 4804/UN4.20.1/PT.01.04/2022 06 September 2022
Perihal : Permohonan Izin Penelitian

Yth. Dekan Fakultas Farmasi Universitas Hasanuddin
Makassar

Dengan hormat disampaikan bahwa mahasiswa Sekolah Pascasarjana Universitas Hasanuddin yang tersebut dibawah ini :

Nama : Amirah Febrianti Ismail / 182305469676
Nomor Pokok : P062202006
Program Pendidikan : Magister (S2)
Program Studi : Ilmu Biomedik

Bermaksud melakukan penelitian dalam rangka persiapan penulisan tesis terkait dengan judul "Perbedaan Ekspresi Angiotensin Converting Enzyme-2 (ACE2) Pada Jaringan Ginjal Tikus Hipertensi Setelah Pemberian Angiotensin Converting Enzyme Inhibitor, Calcium Channel Blocker dan Switching Angiotensin Converting Enzyme Inhibitor Menjadi Calcium Chann".

Sehubungan dengan hal tersebut, mohon kiranya yang bersangkutan diberikan izin untuk penelitian di Laboratorium biofarmasi pada Fakultas Farmasi Unhas.

Atas perkenan dan kerjasamanya diucapkan terima kasih.

a.n. Dekan
Wakil Dekan Bidang Akademik,
Riset dan Publikasi Ilmiah

Prof. Dafniyulim Hidayat, ST., M. Arch., Ph.D.
NIP. 196903081995121001

Tembusan:

1. Dekan SPa Unhas "sebagai laporan"
2. Mahasiswa yang bersangkutan
3. Arsip


Lampiran 3. Surat Izin Penelitian di Lab Farmasi UMI



YAYASAN WAQAF UMI
 UNIVERSITAS MUSLIM INDONESIA
 FAKULTAS FARMASI
 PROGRAM STUDI SARJANA FARMASI
 LABORATORIUM PENGUJIAN PRAKLINIK



Lt. 5 Gedung Laboratorium Fakultas Farmasi Kampus II UMI
 Website : farmasi.umi.ac.id, Email : praktik.farmasi@umi.ac.id

	Nama Lengkap	: Amirah Febrianti Ismail
	NIM	: P062202006
	Institusi	: Universitas Hasanuddin
	No. Hp	: 082396769676
	Alamat E-mail	: febrianti.amirah@yahoo.com

Judul Penelitian	: Perbandingan ekspresi angiotensin converting enzyme-2 (ACE2) pada ginjal tikus hipertensi setelah pemberian obat ace inhibitor, calcium channel blocker, dan switch ace inhibitor menjadi calcium channel blocker
Pembimbing I	: dr. M. Aryadi Arsyad, M.Biomed, Ph.D
Pembimbing II	: Dr. dr. Irfan Idris, M.Kes
Mulai Penelitian	: 11/9/2022
Selesai Penelitian	:

No	Tanggal Penelitian	Nama Kegiatan	Pukul (Masuk)	Pukul (Pulang)	Paraf	Ket

Lampiran 4. Surat Izin Penelitian di HUM-RC UNHAS

 HUM-RC <small>HASANUDDIN UNIVERSITY MEDICAL RESEARCH CENTER science for a better future</small>	ADMINISTRASI	FORMULIR 1
	Nomor : 078/03/FR1/2023	Tanggal : 14 Maret 2023
SURAT PENGANTAR PENELITIAN		

Kepada Yth.
Pembimbing/pendamping,
Ibu Handayani Halik,

Dengan ini menerangkan bahwa peneliti/mahasiswa berikut ini :

Nama : Amirah Febrianti Ismail
NIM : P062202006
Institusi : Sekolah Pascasarjana Ilmu Biomedik Universitas Hasanuddin

Akan melakukan pengambilan data/ analisa bahan hayati :

Pada tanggal : 15 Maret 2023 s/d Selesai
Jumlah subjek : -
Jenis data : Data Primer

Untuk penelitian dengan judul :

“Perbedaan Ekspresi Angiotensin Converting Enzyme-2 (ACE2) pada Jaringan Ginjal Tikus Hipertensi Setelah Pemberian Angiotensin Converting Enzyme Inhibitor, Calcium Channel Blocker, dan Switching Angiotensin Converting Enzyme Inhibitor Menjadi Calcium Channel Blocker”

Harap dilakukan pembimbingan dan pendampingan seperlunya. Terima Kasih.

Staf Administrasi,


HUM-RC
science for a better future

Andi Fidyah Septiani

Lampiran 5. Dokumentasi Penelitian

Pre Induksi



Pengukuran Tekanan Darah



Penguburan Tikus yang Mati



Post Induksi




Pengambilan Jaringan



Penyimpanan Jaringan di Wadah



Pemeriksaan ELISA



RIWAYAT HIDUP PENULIS

Identitas Pribadi

Nama : Amirah Febrianti Ismail
Tempat/Tanggal Lahir : Ujung Pandang, 19 Februari 1998
Alamat : Jl. Arkeologi Raya B/3 Komp. Unhas Antang
No. Telp : 082396769676
Email : febrianti.amirah@yahoo.com
Jurusan : Biomedik Konsentrasi Fisiologi
Fakultas : Pascasarjana Universitas Hasanuddin
Nama Ayah : Ismail Muammil
Nama Ibu : Nur Fatimah Sirajuddin

Riwayat Pendidikan

1. 2003 – 2009 : SD Inpres Baraya I Makassar
2. 2009 – 2012 : SMP Islam Athirah Makassar
3. 2012 – 2014 : International Islamic High School
4. 2014 – 2020 : Pendidikan Dokter Umum Universitas Hasanuddin
5. 2021 – sekarang: Magister Ilmu Biomedik Konsentrasi Fisiologi, Sekolah Pascasarjana Universitas Hasanuddin